Leishmania amazonensis 5659 Leishmaniasis Protective mechanisms in L. amazonensis are unclear. During L. amazonensis infection, BALB/c mice display a mixed profile of both Th1 and Th2 responses, although the implications of this mixed profile are ambiguous. However, the necessity for vaccines to induce a Th1-dominant response for these species of Leishmania appears to be consequential for protection (Campbell et al., 2004). The immune responses induced against L. (L.) amazonensis have showed a distinct pattern from that described for L. (L.) major. While mice that are resistant or susceptible to infection with L. (L.) major exhibit immune responses polarized to Th1 and Th2, respectively, susceptibility to L. (L.) amazonensis can not be correlated to an increased Th2 response (Fedeli et al., 2010). The different Leishmania species cause a broad spectrum of human diseases. L. amazonensis is known to be associated with cutaneous, diffuse cutaneous, and visceral leishmaniasis in South and Central America. The pathological mechanisms responsible for the variable outcomes of infection in humans are not fully understood; however, it is generally agreed that long-lasting immunity against reinfection can be developed in cutaneous leishmaniasis patients. Several vaccination trials have demonstrated that killed L. amazonensis can induce protection from natural infection. However, the efficacy of heat-killed vaccines against Leishmania has been extremely low or highly variable within the same study. Live parasites have been used as a vaccine strategy, and although they are highly effective in inducing immunity, this strategy has been virtually abandoned due to safety issues associated with injecting virulent organisms (Campbell et al., 2003). Baboon Papio cynocephalus 9556 Bank vole Clethrionomys glareolus 447135 Bear Ursus americanus 9643 Birds Passeroidea 175121 Brown Trout Salmo trutta 8032 Buffalo Bison bison 9901 Carnivores Vulpes 9625 Cat Felis catus 9685 Catfishes Siluriformes 7995 Cattle Bos taurus 9913 Chicken Gallus gallus 9031 Chimpanzee Pan troglodytes 9598 chinchillas Chinchillidae 10150 Copper Pheasant Syrmaticus soemmerringii 9067 Deer Cervus elaphus 9860 Deer mouse Peromyscus maniculatus 10042 Dog Canis familiaris 9615 Ducks Anas 8835 Ferret Mustela putorius furo 9669 Fish Hyperotreti 117565 Gerbil Gerbillina 10045 Goat Capra hircus 9925 Gray wolf Canis lupus 9612 Guinea pig Cavia porcellus 10141 Hamster Mesocricetus auratus 10036 Horse Equus caballus 9796 Human Homo sapiens 9606 Macaque Macaca fascicularis 9541 Mongolian Gerbil Meriones unguiculatus 10047 Monkey Platyrrhini 9479 Mouse Mus musculus 10090 None None Parrot Psittacidae 9224 Pig Sus scrofa 9823 Rabbit Oryctolagus cuniculus 9986 Rainbow trout Oncorhynchus mykiss 8022 Rat Rattus 10114 Raven Corvus corax 56781 sei whale Balaenoptera borealis 9768 Sheep Ovis aries 9940 Squirrel Spermophilus richardsonii 37591 Tree shrew Tupaiidae 9393 Trouts, salmons & chars Salmoninae 504568 Turkey Meleagris gallopavo 9103 Vole Microtus ochrogaster 79684 Water buffalo Bubalus bubalis 391902 L. amazonensis CP Protein Vaccine VO_0004199 Subunit vaccine Research subcutaneous injection Complete Freund's adjuvant subcutaneous injection A 500 bp fragment encoding an isoform of cysteine proteinase (CP) from Leishmania (Leishmania) amazonensis was subcloned and expressed in the pHis vector, resulting in a recombinant protein of 24 kDa, rLacys24 (Fedeli et al., 2010). Recombinant protein preparation BALB/c Female BALB/c mice (six per group) were immunized thrice with a 2 week interval with 25 μg of rLacys24 plus complete Freund’s adjuvant (CFA) by the subcutaneous route in the base of the tail. Control animals received PBS or only adjuvant (Fedeli et al., 2010). Immunization of BALB/c mice with rLacys24 plus CFA adjuvant resulted in a low but significant decrease of foot lesions after challenge with L. (L.) amazonensis compared to those exhibited by control mice (Fedeli et al., 2010). Two weeks after the last dose animals were challenged with 2.5 × 10^5 L. (L.) amazonensis amastigotes in PBS in the hind footpad (Fedeli et al., 2010). L. amazonensis DNA vaccine encoding GP46 VO_0011354 DNA vaccine Research VR1012 plasmid Intramuscular injection (i.m.) Intramuscular injection (i.m.) L. amazonensis gp46 DNA vaccine construction cDNAs encoding L. m. amazonensis gp46 antigen was subcloned into the VR1012 plasmid (Dumonteil et al., 2000) BALB/c Susceptible BALB/c mice were immunised with two i.m. injections of 100 microg of plasmid DNA (Dumonteil et al., 2000). Measurement of lesion size indicated that mice immunised with VR012-GP46 were partially protected against infection (Dumonteil et al., 2000). Mice were challenged by the injection of 4 x 10^6 L. m. mexicana parasites in the foot pad to evaluate protection (Dumonteil et al., 2000). L. amazonensis DNA vaccine encoding WD protein VO_0011349 DNA vaccine Research pcDNA3.1/Hygro(−) (Invitrogen) Subcutaneous injection Subcutaneous injection L. amazonensis WD DNA vaccine construction The whole gene insert from the pBK-CMV clone containing the LAWD gene was subcloned into the pET32a plasmid (Invitrogen) for His tag protein expression. To ensure that the ORF would be read in frame, the plasmid was first digested with BamHI and then blunt-ended by a Klenow reaction (Invitrogen) (Campbell et al., 2004). BALB/c Mice (five per group) were immunized in five locations with a total of 100 μg of DNA (50 μg of LAWD and 50 μg of IL-12) per mouse: four injections in both sides of the inner and outer thigh muscles of the hind legs (∼50 μl/site) and one subcutaneous injection in the left hind foot (∼5 μl/site) (Campbell et al., 2004). DNA vaccination in BALB/c mice with the LAWD (for Leishmania antigenic WD protein) and IL-12 genes significantly delayed lesion development from challenge with Leishmania amazonensis, which correlated with a dramatic reduction in parasite burdens (Campbell et al., 2004). Mice were boosted twice at 3-week intervals and then challenged 3 weeks after the last immunization with 2 × 10^5 metacyclic promastigotes in the right hind foot (Campbell et al., 2004). L. amazonensis M2 protein vaccine VO_0011355 Subunit vaccine Research Intraperitoneal injection (i.p.) Killed Corynebacterium parvum Intraperitoneal injection (i.p.) L. amazonensis M2 Recombinant protein preparation M-2, a 46-kDa promastigote-specific glycoprotein was isolated. The protein was further purified by removal of detergent with an anionexchange column(Champsi and McMahon-Pratt, 1988). CBA BALB/c, CBA, and C57BL/6 mice were immunized intraperitoneally with M-2 at a final concentration of 0.03 mg/ml. The amount of C. parvum used in immunizations 2 and 3 was reduced to 0.05 mg per immunization (Champsi and McMahon-Pratt, 1988). Immunization of CBA mice with the M-2 glycoprotein of L. amazonensis and C. parvum adjuvant resulted in complete protection against a challenge infection of 10^4 and 10^6 late log-phase promastigotes of L. amazonensis. In the BALB/c strain, complete protection was observed in some of the immunized animals (28 to 50%); in the rest of the mice the onset of infection was significantly delayed. Protective immunity for C57BL/6 mice was observed only at the low infecting dose (10(4) L. amazonensis organisms) (Champsi and McMahon-Pratt, 1988). Animals were rested for 2 to 4 weeks after final immunization and challenged in the right hindfoot with late-log-phase promastigotes. Parasites used for infections were passaged a maximum of four times. Challenge doses of 10^3, 10^4, 10^5, and 10^6 were used (Champsi and McMahon-Pratt, 1988). licensed Leishmaniasis human vaccine Generic Unknown VO_0012158 Live, attenuated vaccine Licensed A generic representation of live, attenuated vaccines historically utilized to prevent leishmaniasis in humans. These vaccines contain weakened Leishmania parasites designed to stimulate protective immunity without causing disease. CP cysteine proteinase Leishmania amazonensis VO_0011295 30142041 30142042 AAN34826.1 CDD:185513 CDD:214853 CDD:278538 CDD:239068 5659 ? cysteine proteinase 6.56 36075.3 418 forma: amastigote >gi|30142041|gb|AY141759.1| Leishmania mexicana amazonensis clone 2A1 cysteine proteinase mRNA, complete cds CCGTCACGCCCTTCTCGTGCGCACGTTGCAGAACCAGGATCGGCAAAGATGGCGCGCCGCAACCCCCTTT TGTTTGCGATAGTGGTGACGATCCTGTTCGTGGTGTGCTACGGTTCCGCTCTCATCGCCCAGACACCCCC CGCCGTCGACAACTTCGTTGCCTCAGCGCATTACGGAAGTTTTAAGAAGCGCCACAGTAAGGCCTTCGGC GGGGACGCCGAGGAGGGTCACCGCTTCAATGCCTTCAAGCAGAACATGCAGACAGCCTACTTCCTCAACA CGCAGAACCCCCACGCGCACTACGACGTGTCCGGCAAGTTCGCGGACCTCACCCCGCAGGAGTTCGCCAA GCTGTACCTGAATCCCGACTACTACACGAGCCACCTCAAGGATCACAAGGAGGACGTGCACGTCGACGAC AGCGCCCCCAGTGGTGTGATGTCGGTGGACTGGCGTGATAAGGGTGCCGTGACGCCGGTGAAGAACCAGG GATTATGCGGCTCGTGCTGGGCCTTCTCCGCCATTGGCAACATCGAAGGTCAGTGGGCTGCAAGCGGCCA CTCGTTGGTTTCACTGTCAGAACAGATGCTCGTGTCGTGCGACAACGTCGATGAAGGGTGCAACGGCGGG CTGATGGACCAGGCAATGAACTGGATCATGCAGAGTCACAACGGCAGTGTGTTCACGGAGGCCAGCTATC CCTACACCTCTGGCGGCGGCACCAGACCGCCGTGCCATGACGAAGGTGAAGTTGGCGCTAAAATCACCGG TTTCCTCTCCCTGCCGCACGACGAGGAGCGGATCGCGGACTGGGTGGAGAAGAGAGGCCCCGTCGCCGTC GCCGTCGACGCGACAACCTGGCAGCTGTACTTTGGCGGTGTGGTCTCCCTCTGCCTCGCGTGGTCGCTCA ACCACGGTGTGCTCATTGTCGGCTTCAACAAAAACGCGAAACCGCCGTACTGGATCGTGAAGAACTCGTG GGGCTCCTCGTGGGGTGAGAAGGGGTACATCCGCCTTGCCATGGGCAGCAACCAGTGCATGCTCAAGAAT TACCCCGTGTCGGCCACGGTTGAAAGCCCCCACACCCCACACGTGCCGACGACAACGGCCTAGCTGGAGC CCAGGCCCACGGCGCCTGGGCGAATGAGCTGCTTTTTTTTTCGAGTGGGTGCTCGAGGCTGTGCACAAGC ACGACCTATCCGACCTGTGTGTGCCTGAAGCGCCAGAATGGCGGCTCTGCCCAGGTGACCTGTGGCAAAC CCGAGACGGCGGAGCTTCTCTACAACTGGCCGGGTTGCTCCGAGGCTGCCACCGAGGCCTGCATGCCGCT GAACAATATGTATGCGCAGCTACGCCGGCTACCTCCAGAACGTCTGCACTGCGTTCGTCGCTTGCACTGA GAACCAACGACGCCGTCTCTGACTTGACCAAGCCAACCATCTTGGGCCAACCACACGTCCCGTACGCGAG GCACGCGGGGATCCAGGACTGGCAGGATCCACTGCGCACTATACGCCTCAGCTGCACCGATGCGGATCCC TCCCTCAAAAAAAAAAAAAAAAAAAAAA >AAN34826.1 cysteine proteinase [Leishmania amazonensis] MARRNPLLFAIVVTILFVVCYGSALIAQTPPAVDNFVASAHYGSFKKRHSKAFGGDAEEGHRFNAFKQNM QTAYFLNTQNPHAHYDVSGKFADLTPQEFAKLYLNPDYYTSHLKDHKEDVHVDDSAPSGVMSVDWRDKGA VTPVKNQGLCGSCWAFSAIGNIEGQWAASGHSLVSLSEQMLVSCDNVDEGCNGGLMDQAMNWIMQSHNGS VFTEASYPYTSGGGTRPPCHDEGEVGAKITGFLSLPHDEERIADWVEKRGPVAVAVDATTWQLYFGGVVS LCLAWSLNHGVLIVGFNKNAKPPYWIVKNSWGSSWGEKGYIRLAMGSNQCMLKNYPVSATVESPHTPHVP TTTA Protective antigen A 500 bp fragment encoding an isoform of cysteine proteinase (CP) from Leishmania (Leishmania) amazonensis was subcloned and expressed in the pHis vector, resulting in a recombinant protein of 24 kDa, rLacys24. Immunization of BALB/c mice with rLacys24 plus CFA adjuvant resulted in a low but significant decrease of foot lesions after challenge with L. (L.) amazonensis compared to those exhibited by control mice [Ref1351:Fedeli et al., 2010]. Gp46 Leishmania amazonensis VO_0011292 159320 159321 AAA29234.1 CDD:178695 CDD:275380 5659 ? surface membrane glycoprotein GP46/M-2 8.21 46877.99 560 hypothetical protein; Provisional >gi|159320|gb|M38368.1|LEIGP46M2 L.amazonensis surface membrane glycoprotein GP46/M-2 gene, complete cds ATGGCGCAGTGCGTGCGTCGGCTGGTGCTGGCGGCGCCCCTCGCCGCTGTGGTGGCGCTGCTGCTGTGCA CGAGCAGTGCACCGGTGGCGCGTGCTGCGGGGACGAGCGACTTCACTGGTGCGCAGCAGAAGAACACGCT GACGGTGCTGCAGGCGTTTGCGCGTGCGATCCCTGCGCTTGGGGACACGTGGACGGGCAGCGACTTCTGC TCGTGGGAGCACATCATCTGCTACTCCTCCGGCGTCGGCGTGTGGATGCACAATGTGGATTATACCGGCA CGCTGCCGGAGATGCCTGCGAGCGTCGACTACAAGGACGTCATGATCTTGGCACTGGACTTCGGCGCAAT GGGCCAGGGGCTGAGCGGGACGCTGCCCCCCTCATGGAGCTCGATGAAGCACCTGATCGTTCTGGATCTG GAGGGCACTAAGGTGTCCGGCACGCTGCCGCCCGAGTGGAGTGAGATGACGAGTGCTGAGGCCCTGCAGC TGGAGAACTGCGGTCTGTCCGGGAGTCTGCCCACCTCGTGGTCTTCGATGCCGAAGCTGCGTATCGTCTC ACTGAGCGGCAACCACTTCTGCGGGTGCGTGCCCGACTCGTGGAGGGAGAAGGACCGCCTCGATGTGACC ATCGAGGAATGGCACATGGGCGAGGACTGCAAGCTTGCTAACGCCTGCCGCCCGACTGCTGCTCCGGGAA CGACCACGACTAACCCGCCCACCACCACCGGCACCCCAGCAGCCTCCTCTACTCCTTCTCCAGGGTCGGG GTGCGAGGTGGATGGGTGTGAGGTGTGCGAGGGGGACTCCGCTGCGCGGTGCGCCAGGTGCCGTGAGGGC TACTCCCTGACGGACGAGAAGACGTGCCTGGGCGAACCACGATGGCGGCGTGGCGGCGGCGTCGAGCGGA CGGCTGGCTGCCGCTGCTGTGTGGGCGGCTGTGCTGTTGAGCGTGGGGCTGGTGGCGTGAGGGTGCGGCG GGCCCCTCTTCTCTGTGGTGCCCCTGGTGCCTGCCCTCGCCCCCGGCACGGCGTCGTCGCTGCCCTCTCA CCCCCACCAGCCGACGGGGAGACCGACAGCCACACGCGCACGCGCACACGCCGTCGTGCATCGCGTGTGC TTTCCGCCGTTGTGGCGCCTGCGCGGATGCACGGGCATGCGGAGGCGTGCATGCGTGTGCGCGTGCCGGC TCTTGTGTGTCTCTCCGTGTGGCCAGCAGTCGGCACCCGCCGCCGATCGAATGTGCGCGCGGCGGCGGTG TGTCGCCTTGGACAGCGGAGATGCGGCGCCCGCCCCTCGCCGTGTGCCTCGGTCTGCGTGTCGTGGCCGC GCGAGCGACGTACGGAGTGCGCGTGTCCGGCCCTCTTCGACGGGGCTCGCTTGCGGTGCTGTGCTCTCGT GGTCTGTGCCGGTGCTGCCCCGGCGGGGTGA >AAA29234.1 surface membrane glycoprotein GP46/M-2 [Leishmania amazonensis] MAQCVRRLVLAAPLAAVVALLLCTSSAPVARAAGTSDFTGAQQKNTLTVLQAFARAIPALGDTWTGSDFC SWEHIICYSSGVGVWMHNVDYTGTLPEMPASVDYKDVMILALDFGAMGQGLSGTLPPSWSSMKHLIVLDL EGTKVSGTLPPEWSEMTSAEALQLENCGLSGSLPTSWSSMPKLRIVSLSGNHFCGCVPDSWREKDRLDVT IEEWHMGEDCKLANACRPTAAPGTTTTNPPTTTGTPAASSTPSPGSGCEVDGCEVCEGDSAARCARCREG YSLTDEKTCLGEPRWRRGGGVERTAGCRCCVGGCAVERGAGGVRVRRAPLLCGAPGACPRPRHGVVAALS PPPADGETDSHTRTRTRRRASRVLSAVVAPARMHGHAEACMRVRVPALVCLSVWPAVGTRRRSNVRAAAV CRLGQRRCGARPSPCASVCVSWPRERRTECACPALFDGARLRCCALVVCAGAAPAG Protective antigen cDNAs encoding L. m. amazonensis gp46 antigen were subcloned into the VR1012 plasmid, and susceptible BALB/c mice were immunised with two i.m. injections of 100 microg of plasmid DNA. Mice were challenged by the injection of 4 x 10^6 L. m. mexicana parasites in the foot pad to evaluate protection. Measurement of lesion size indicated that mice immunised with VR012-GP46 were partially protected against infection [Ref1348:Dumonteil et al., 2000]. M2 Leishmania amazonensis VO_0011291 2828562 2828563 AAC08302.1 CDD:240315 CDD:153108 5659 ? ribonucleotide reductase M2 subunit 5.07 38155.95 424 hydroxyurea-resistant strain derived from LV-78; cloned from extrachromosomal amplified circular DNA >gi|2828562|gb|AF005247.1| Leishmania mexicana amazonensis extrachromosomal element ribonucleotide reductase M2 subunit gene, complete cds ATGAAACCGGTTGCGGCTGGCGCCGAGGTGCTGCCGGCGGACAAGGTTGCCCAGGGGACGAACGCCGAGG AGGAGCCGCTGCAGCAGGAGAACCCGTTCCGCTACGTCCTCTTCCCAATCCAGTACCATGACATCTGGCG GAAGTACAAGGAGCAGGAGAGCTGCATCTGGACGGTGGAGGAGATCGACCTGGGCAACGACATGAAGGAC TGGGCAACGCTGAACGACGGTGAGCGGCACTTCATCAAGCATGTGCTTGCCTTCTTCGCCGGCAGCGACG GCATAGTCATCGAGAATCTTGCGCAGCGCTTCATGAGCGACGTGAAGGTGCCAGAGGCGCGCGCGTTCTA CGGGTTCCAGCTGATGATGGAGAACATCCACTCGGAGACGTACTCTGTGCTGCTGGACACGTACATCACG GACAGCGAGGAGAAGCTGCGGCTGCTGCACGCGATACAGACGATCCCGTGCATCCAGAAGAAGGCGGAGT GGCCCGTGCGGTGGATCGGGAGCAGCGCGAGCTTTCAGCAGCGGCTGATCGGCTTTGCCGCGGTGGAGGG CATTTTCTTTTCCGGGTCGTTCTGCGCGCTGTTCTGGCTGAAGAAGCGCGGTCTGATGCCAGGGCTGACG TTCAGCAACGAGCTCATCTCGCGCGACGAGGGTCTACACACGGACTTCGCATGCCTGCTGTACAACTCGC ACATCAAGCACAAGCTGCCGCGCGAGCGCGTGCTGGAGATCATCGTGGATGCGGTGAACATCGAGCGTGA GTTCATCTGCGACGCGCTGCCGGTGCGGCTGATTGGCATGAACGCGGAGCTGATGGCGCAGTACATCGAG TTCGTCGCGGACCGGCTGCTGGTGTCGCTCGGCGAGGAGAAGCACTACCGCTCGACGCAGCCGTTCGACT TCATGGAGATGATCTCGCTGCAGGGCAAAACGAACTTCTTCGAGAAGAGGGTGGGGGAGTACCAGAAGGC CGGCGTGATGAGCACGGAGGGCACGTCGAAAAAGTTCTCCCTCTCGGAGGACTTCTAA >AAC08302.1 ribonucleotide reductase M2 subunit [Leishmania amazonensis] MKPVAAGAEVLPADKVAQGTNAEEEPLQQENPFRYVLFPIQYHDIWRKYKEQESCIWTVEEIDLGNDMKD WATLNDGERHFIKHVLAFFAGSDGIVIENLAQRFMSDVKVPEARAFYGFQLMMENIHSETYSVLLDTYIT DSEEKLRLLHAIQTIPCIQKKAEWPVRWIGSSASFQQRLIGFAAVEGIFFSGSFCALFWLKKRGLMPGLT FSNELISRDEGLHTDFACLLYNSHIKHKLPRERVLEIIVDAVNIEREFICDALPVRLIGMNAELMAQYIE FVADRLLVSLGEEKHYRSTQPFDFMEMISLQGKTNFFEKRVGEYQKAGVMSTEGTSKKFSLSEDF Protective antigen Immunization of CBA mice with the M-2 glycoprotein of L. amazonensis and C. parvum adjuvant resulted in complete protection against a challenge infection of 10^4 and 10^6 late log-phase promastigotes of L. amazonensis. In the BALB/c strain, complete protection was observed in some of the immunized animals (28 to 50%); in the rest of the mice the onset of infection was significantly delayed. Protective immunity for C57BL/6 mice was observed only at the low infecting dose (10(4) L. amazonensis organisms) [Ref1347:Champsi and McMahon-Pratt, 1988]. WD Leishmania amazonensis VO_0011290 38455440 38455441 AAR20840.1 CDD:225201 CDD:238121 CDD:293791 5659 ? antigenic WD protein 6.52 70626.83 743 WD40 repeat [General function prediction only]; COG2319 >gi|38455440|gb|AY457171.1| Leishmania amazonensis antigenic WD protein mRNA, complete cds CCCTCCCACTACCACGCAGCTTGTCATATCATACTGTGTTTCATTGTATGCATCCGGCGTGAGCAATTCT TTGTGTCCTCAACCGCTCTTTCCTTTCGTCTTTCATCGCTGTGCTTCCTCTCCCCTCAGCGCCCCCCCCT CTCCCTTCTCGCACACGCACGCACAGTGGCACAGATACATACAGAGGCACTCCTCTTCTCCCTACACTAT CTTGCAGTGCCCTCTTCTTCCCCCGCCTCTTACTCTGCCCGTCCCTCTCCGACTCTCTTTCACGTTTCGC AACACCAGTATCAACCATGGCCAAGGAGAAACTCGGCTTCAAGATCCAGGGGAAGACCGTCTCCTACGAG GGTTACCCCGAGCGTCCGCCAAGGGACCTGATGGACATCTTGGTCAAAATGGGTGTCGGCGAAGCTGCCG TGGTGACCACCTTTCTAGAAAATATTGAGAACCACCGGGAGTTCACCGACGAGCAGGTGATGGTGATGTA CAACGAAGCAAAAATGACGCGCGAGAAGAAGGCTCGTGCGAAGGCCGGCAACCAGGGTGACTCAGCCGCT GCCGCCGCCGCTCCATCGGGCGCCGCCGATGAGGCGGAGAAGCCGCAGAAGATCCTTCTTTCCTACCGCG GCAAGCAGCTTTCCTACGTAGGTTTGCCCAGCGGCAAGCGCAACGCCGTGCTGCAACTCCTCTCCAAGCA AGAGGAGCTCACCCGGGAGCTTGCAGTGGAGACGTTCCGCACGAACCTGCCCAGTGATCCGTCCACGGAG GAGGAGATTTGGATCTTGGTGCAGGCAGTCAAAGATCGCAAGAGTAGGAAGAGCCAAGCGAAGGGTCAGG ATGGCGAAAGGTCCGGCGGTAACGGTGCGACTGCGTCGCTTGGGGCAGGCAGCAGCGCCATGGACAGCAT AACCGGTATGTCCGAGAGGGAGCGCGACGACCTGAACAACTTCATTCTTCAGGTGCTGCAGCAGCCAGCG CCGGATGTGGCCGCCCTCTTACATGAGAATCCGAAACCGCGCAAAGACACGGAAGACAATGCGGAGCTGG CACTGACAGCGCGCATGTCGGGTAAGATTCCGGTTTACCTGCAGGAAGAGAACACCAGCAGCACGAAGCT CATCTACGCCACGCCCCACATGAGCTTCGAAGATTTTTCTACCATTGTCGAGAAGAAGTGTGGCCGCAAG TTGTCGCTGTCCTTCTACGACGGCGACGACCTCATCATGATGGATGATGACGACGTGCTGGCCATGTTTC TCGAAATGACAGTGCAGAACGACCCAAAGAAGGTGCGCCTCATTTGCTCCAACCCTGGAGTCCCAAGGAA GGCGGCGGATGACCGGATGATGGAAAACCGTCAAAATACCTTCAGCGGTCTTCCGCAGGTCTCAACGACC AAGGCATTGGCGTACTCGAACGGCGAGCTCAACGTCGCGGAGGCTCGCACCTACTTTGGCCACTCTCTTG CCGTCTACTGCTGCTGCTTCTCGCCAAGGGGCGACATGTTCGTTACGGCAAGTCGCGACCGCACCGTCCG CCTGTGGAACTTGCGCACCGGTGTCTCCACAGTCATGAAAGGCGGGCACAACGGCTTTGTGCTGTCTTGC GACTACTCGCCAAAGGGCAACCGCGTCGCTTCCTCTTCTGATGACCGCACTATCAAACTGTGGAACACGT CGTCATGCAACAAGGTTGCCACACTTAAAGGGCACGAGGACAAGGTATACTGCGTCAAGTACAACTCTAG CGGAGATCTCCTCGTGTCCGCCTCTTGCGACACCACAGTGCGCGTGTGGAACGCCGAAAGTCAGGCGAAG CTGGTGACGCTGAGGGGCCACACCCTCGCCGTTTTTTCCTGCGCCTTCAGCAACAGCGATAATGGAAAGT TCGTCGTCTCCGGCAGCGATGACCGCGTTATAAAGCTGTGGGACTGGGGCGCCGGCAGAGAGATCCTGTC GCTGGTGGGTCACATCGGCACCGTGTGGACGGTTGTCTTCTCCCACAACGACAGGTACGTTCTCAGTGGC AGCATGGACTATGAGCTCATTCTCTGGGATTCAATGACTGGCGCTCGCCTGCGCTCGATGGACGGGCACA AGACATCGGTGCACCACGCCATCTTCTCCGAGGACGACGCATACATCTTCTCCTGCGCCCGCGACTGGAG CGTCATGGTGTGGCGCACCGAAGATGGCGAGCATGTAGAGACCATCATCGGTCACCTCAGCACTGTCTAC CACATGGACATCAGCGAGGACAAGTTGCTCACCTGCTCTCTTGATGACAAGATCAAGCTGTGGAATATCA GGCGCCACTGAAGTTGAGCACCAGCGGAAAATGTGGTAGTGCGAACACTGGCGGGAGGGGCACGTGCCAG CCGCAACCGAGAAAGAGGTGTGGGCGGGAAGGCACGTGATAGGTGATACAGACACTGTACCCGTACACCA TTCCTCTTTTCAGCAGCAGTCCTGCACACAGAAAGACACTCGGATTTTTCATTGACAAATCAGGTGGGTC TGAAGACGATTTCAAGAAGAAGCGAGCGTTCGTATGTACCGCCCTCCTCCCTCCACCGATACTGCAACAC ACACACACACACATTTTACGGTCTTGTCTACTTTTCTTCGTTTCGCTCTCGTCAGTTCCACCGAGTCCTG GCTGCGTTTGGGTGCCACGCGTGTGAATGTGTGAGCGCCACCGTTGGTCGACCCTTTTCGCTTTCCTGCA TGCTTTTTTTCTTTTCGTATCTCTACGTCCTGCTCACAGCGCATCGACCTCTGCCAGAGGATATCATTTG GCAGTGTCGTTTCTTTTGCTCTTTTTCTCTCTTTGCCACCGTTCTTGCGGGCCAACGGCACCGTGCTCCC CGCTTCTCTGTCTCGCGACCTCGACATTCATCTCTTCCATGCTTCTCCCTCTCCCCCTCCGTCTCCCCAG CTTTTTGTCGTTTGTGCATTCTCCTCTTTTCTTAAGTGATGCTTCAAAGGAAACGAAAAAAAAAAAAAAA AA >AAR20840.1 antigenic WD protein [Leishmania amazonensis] MAKEKLGFKIQGKTVSYEGYPERPPRDLMDILVKMGVGEAAVVTTFLENIENHREFTDEQVMVMYNEAKM TREKKARAKAGNQGDSAAAAAAPSGAADEAEKPQKILLSYRGKQLSYVGLPSGKRNAVLQLLSKQEELTR ELAVETFRTNLPSDPSTEEEIWILVQAVKDRKSRKSQAKGQDGERSGGNGATASLGAGSSAMDSITGMSE RERDDLNNFILQVLQQPAPDVAALLHENPKPRKDTEDNAELALTARMSGKIPVYLQEENTSSTKLIYATP HMSFEDFSTIVEKKCGRKLSLSFYDGDDLIMMDDDDVLAMFLEMTVQNDPKKVRLICSNPGVPRKAADDR MMENRQNTFSGLPQVSTTKALAYSNGELNVAEARTYFGHSLAVYCCCFSPRGDMFVTASRDRTVRLWNLR TGVSTVMKGGHNGFVLSCDYSPKGNRVASSSDDRTIKLWNTSSCNKVATLKGHEDKVYCVKYNSSGDLLV SASCDTTVRVWNAESQAKLVTLRGHTLAVFSCAFSNSDNGKFVVSGSDDRVIKLWDWGAGREILSLVGHI GTVWTVVFSHNDRYVLSGSMDYELILWDSMTGARLRSMDGHKTSVHHAIFSEDDAYIFSCARDWSVMVWR TEDGEHVETIIGHLSTVYHMDISEDKLLTCSLDDKIKLWNIRRH Protective antigen DNA vaccination in BALB/c mice with the LAWD (for Leishmania antigenic WD protein) and IL-12 genes significantly delayed lesion development from challenge with Leishmania amazonensis, which correlated with a dramatic reduction in parasite burdens [Ref1346:Campbell et al., 2004]. Campbell et al., 2003 journal Campbell K, Diao H, Ji J, Soong L 2003 71 11 6270-6278 Infection and immunity Campbell et al., 2004 journal Campbell K, Popov V, Soong L 2004 72 4 2194-2202 Infection and immunity Champsi and McMahon-Pratt, 1988 journal Champsi J, McMahon-Pratt D 1988 56 12 3272-3279 Infection and immunity Duarte et al., 2017 journal Duarte MC, Lage DP, Martins VT, Costa LE, Carvalho AMRS, Ludolf F, Santos TTO, Vale DL, Roatt BM, Menezes-Souza D, Fernandes AP, Tavares CAP, Coelho EAF 2017 222 2 251-260 Immunobiology Dumonteil et al., 2000 journal Dumonteil E, Andrade-Narvarez F, Escobedo-Ortegon J, Ramirez-Sierra MJ, Valencia-Pacheco G, Flores-Serrano A, Canto-Lara S, Arjona-Torres A 2000 104 135-141 Developments in biologicals Fedeli et al., 2010 journal Fedeli CE, Ferreira JH, Mussalem JS, Longo-Maugéri IM, Gentil LG, dos Santos MR, Katz S, Barbiéri CL 2010 124 2 153-158 Experimental parasitology